Takeda estimates £162.50 million hit to operating loss as Novartis withdraws from European approval for XiidraInvezz • 06/29/20
Japan's Takeda expects $200 million operating loss related to Novartis' Xiidra withdrawalReuters • 06/29/20
Exclusive: Blackstone, Taisho Pharma among final bidders for Takeda's Japan OTC unit - sourcesReuters • 06/19/20
Takeda Pharmaceutical Company Limited (TKPHF) on Q4 2019 Results - Earnings Call TranscriptSeeking Alpha • 05/13/20
CSL Behring and Takeda Pharmaceutical Are Leading a Coalition to Develop a COVID-19 Hyperimmune TherapyThe Motley Fool • 04/08/20
Big Pharma's Fight Against the Coronavirus Pandemic: Good News and Bad NewsThe Motley Fool • 03/19/20